HK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%

Stock News

Jan 05

MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.

The company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.

Specifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.

Furthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.

Notably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.

CITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.

Concurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.

Looking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1185164871"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185164871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185164871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185164871","market":"nz","top_or_hot":-1,"title":"HK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%","media":"Stock News","content":"<p>MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.</p>\n<p>The company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.</p>\n<p>Specifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.</p>\n<p>Furthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.</p>\n<p>Notably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.</p>\n<p>CITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.</p>\n<p>Concurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.</p>\n<p>Looking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-05 14:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.</p>\n<p>The company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.</p>\n<p>Specifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.</p>\n<p>Furthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.</p>\n<p>Notably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.</p>\n<p>CITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.</p>\n<p>Concurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.</p>\n<p>Looking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1185164871","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185164871","pubTimestamp":1767593193,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million. The company recently announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1583":"高瓴概念","02160":"微创心通-B","BK1100":"医疗保健设备","TAVI":"Tavia Acquisition Corp"},"translate_title":"港股动向|MP心通-B(02160)再升超10%全年TAVI产品植入物飙升近350%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1,"TAVI":1},"content_text":"MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.\nThe company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.\nSpecifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.\nFurthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.\nNotably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.\nCITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.\nConcurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.\nLooking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}